{
 "name": "友霖",
 "slug": "tw-4166",
 "aliases": [
  "友霖生技醫藥股份有限公司",
  "OP",
  "4166"
 ],
 "ticker": "4166",
 "industry": "生技醫療業",
 "website": "https://academy.oppharma.com/",
 "summary": "友霖（4166）是上櫃的生技醫療類股公司，2008 年成立，2025 年上櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "友霖生技醫藥股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "英文簡稱",
   "value": "OP",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心上櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "上櫃日期",
   "value": "2025-08-21",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "成立日期",
   "value": "2008-02-01",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "董事長",
   "value": "蔡正弘",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "總經理",
   "value": "黃春桐",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "實收資本額",
   "value": 2430350890,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "勤業眾信聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "公司網址",
   "value": "https://academy.oppharma.com/",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "月營收（2026-09）",
   "value": 148829,
   "unit": "新台幣千元",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔數值、單位與as_of保留；2026-10-22重開官方OpenAPI逐值核對，資料年月11509、出表日期1151017，欄位：營業收入-當月營收；僅更正不符白名單的舊二手來源網址。"
  },
  {
   "claim": "月營收年增率（2026-09）",
   "value": 41.18,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔數值、單位與as_of保留；2026-10-22重開官方OpenAPI逐值核對，資料年月11509、出表日期1151017，欄位：營業收入-去年同月增減(%)；僅更正不符白名單的舊二手來源網址。"
  },
  {
   "claim": "累計營收年增率（2026 年 1 月至 09 月）",
   "value": 20.48,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔數值、單位與as_of保留；2026-10-22重開官方OpenAPI逐值核對，資料年月11509、出表日期1151017，欄位：累計營業收入-前期比較增減(%)；僅更正不符白名單的舊二手來源網址。"
  },
  {
   "claim": "管線：Methydur（思有得；ORADUR-methylphenidate）",
   "value": "注意力不足過動症｜已獲TFDA上市許可並在台銷售｜台灣",
   "unit": "",
   "as_of": "2025-07-29",
   "source": "https://mopsov.twse.com.tw/nas/STR/416620250728M001.pdf",
   "note": "PDF第2頁報告日期2025-07-29；檔名20250728為上傳命名，不作as_of。NCT02450890、NCT02704390。"
  },
  {
   "claim": "管線：Tonvasca（同抑脂；pitavastatin／ezetimibe）",
   "value": "原發性高膽固醇血症或混合型高血脂症｜新複方新藥已獲TFDA上市許可｜台灣",
   "unit": "",
   "as_of": "2025-07-29",
   "source": "https://mopsov.twse.com.tw/nas/STR/416620250728M001.pdf",
   "note": "NCT04643093；同抑脂2/10mg之複方與對照成分由試驗登錄及法說第26頁交叉核對。"
  },
  {
   "claim": "管線：1PL105（tofacitinib ER 11mg）",
   "value": "類風濕性關節炎｜FDA Paragraph IV ANDA最終核准（Final Approval），準備上市｜美國",
   "unit": "",
   "as_of": "2026-06-10",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01?companyId=4166",
   "note": "發言日期 2026-06-10 06:49:20；主旨 公告本公司Tofacitinib之美國挑戰專利學名藥 (Paragraph IV)申請，通過美國FDA藥證審查， 取得審查核可；序號 4；enterDate=1150610。 最終核准僅11mg；不是22mg的核准狀態。原文Final Approal為拼字誤植，本fact採標準術語。"
  },
  {
   "claim": "管線：1PL105（tofacitinib ER 22mg）",
   "value": "類風濕性關節炎｜FDA暫定審查核可（tentative approval）｜美國",
   "unit": "",
   "as_of": "2026-06-10",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01?companyId=4166",
   "note": "發言日期 2026-06-10 06:49:20；主旨 公告本公司Tofacitinib之美國挑戰專利學名藥 (Paragraph IV)申請，通過美國FDA藥證審查， 取得審查核可；序號 4；enterDate=1150610。 22mg須待專利到期後準備上市；不得寫成已取得最終上市核准。"
  },
  {
   "claim": "管線：Vancomycin hydrochloride（口服膠囊）",
   "value": "口服結腸炎治療｜已取得US FDA及TFDA上市許可｜美國、台灣",
   "unit": "",
   "as_of": "2025-07-29",
   "source": "https://mopsov.twse.com.tw/nas/STR/416620250728M001.pdf",
   "note": "來源第8頁列Vacomycin為簡報拼字；第36頁包裝寫Vancomycin Hydrochloride Capsules 125mg、250mg，以包裝成分名記錄。"
  },
  {
   "claim": "管線：Pitator／Zulitor（pitavastatin）",
   "value": "高膽固醇血症｜已取得TFDA及US FDA上市許可｜台灣、美國",
   "unit": "",
   "as_of": "2025-07-29",
   "source": "https://mopsov.twse.com.tw/nas/STR/416620250728M001.pdf",
   "note": "法說第8頁載pitavastatin之美台藥證；第29頁載商品名與成分，未將兩商品名推定為同一市場商品名。"
  }
 ],
 "responses": [],
 "provided_by": "public_sources",
 "verified_by": "Drugnews｜藥時事",
 "verified_at": "2026-10-22",
 "disclosure": "Drugnews 依公開來源（公司公告、公開資訊觀測站、試驗登錄、主管機關文件）整理，於 verified_at 逐條核對來源；未經公司審閱。",
 "url": "https://drugnews.com.tw/companies/tw-4166.json",
 "generated_at": "2026-10-23T01:06:05.573Z"
}